Skip to main content

Table 2 The incidence of expression of CCL2, CCL5, TNFα and IL-1β in tumor cells and in adjacent normal breast epithelial cells in DCIS and IDC patients

From: Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition

Expression of chemokines/cytokines
in 		Number of patients (%)
  With CCL2 expression With CCL5 expression With TNFα expression With IL-1β expression
   DCIS  
Breast malignant cells 11/27 (40.7%) 16/27 (59.2%) 13/27 (48.1%) 15/27 (55.5%)
Adjacent normal breast epithelial duct cells 5/27 (18.5%) 7/27 (25.9%) 3/27 (11.1%) 6/27 (22.2%)
p value 0.03 0.01 0.002 0.003
   IDC-no-relapse  
Breast malignant cells 10/19 (52.6%) 15/19 (78.9%) 14/19 (73.7%) 13/19 (68.4%)
Adjacent normal breast epithelial duct cells 1/19 (5.3%) 1/19 (5.3%) 0/19 (0.0%) 1/19 (5.3%)
p value 0.003 0.0002 0.0001 0.0005
   IDC-with-relapse  
Breast malignant cells 15/29 (51.7%) 17/29 (58.6%) 24/29 (82.7%) 25/29 (86.2%)
Adjacent normal breast epithelial duct cells 3/29 (10.3%) 2/29 (6.9%) 6/29 (20.7%) 8/29 (27.6%)
p value 0.001 0.0001 <0.0001 <0.0001
  1. The expression CCL2, CCL5, TNFα and IL-1β was determined by IHC in serial biopsy sections of primary tumors of the breast taken at the time of diagnosis, from patients diagnosed with DCIS, IDC-no-relapse, or IDC-with-relapse. In this analysis, the incidences of expression of the four factors were determined in the malignant cells and in adjacent normal breast epithelial cells, in the same biopsy. Therefore, this analysis included only patients in whom normal ducts and breast tumor cells were detected in the same biopsy: DCIS - n = 27; IDC-no-relapse - n = 19; IDC-with-relapse - n = 29. The incidence of CCL2, CCL5, TNFα and IL-1β expression in the normal epithelium was not significantly different between DCIS and IDC-no-relapse, and also did not differ significantly between DCIS and IDC-with-relapse patients. The expression of the proteins was determined by antibodies whose binding specificity in IHC was verified.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us